Pregabalin for the treatment of generalized anxiety disorder: An update

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 883-892

  Baldwin, David S ^a,b,c   Ajel, Khalil ^c   Masdrakis, Vasilios G ^d   Nowak, Magda ^a   Rafiq, Rizwan ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Efficacy; Generalized anxiety disorder; Pregabalin; Tolerability

Indexed keywords

4 AMINOBUTYRIC ACID; AGOMELATINE; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CITALOPRAM; DIAZEPAM; DULOXETINE; ESCITALOPRAM; GLUTAMIC ACID; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIFLUOPERAZINE; VENLAFAXINE; VORTIOXETINE; ZIPRASIDONE;

ACUTE DRUG ADMINISTRATION; ADJUVANT THERAPY; BINDING AFFINITY; CELL HYPOXIA; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FIBROMYALGIA; FOCAL EPILEPSY; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; LIVER DYSFUNCTION; MENTAL DISEASE; META ANALYSIS (TOPIC); NAUSEA; NERVE CELL; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; PERIPHERAL EDEMA; PHYSICAL DISEASE; PLEURA EFFUSION; POSTHERPETIC NEURALGIA; PRESYNAPTIC NERVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOM; TRANQUILIZING ACTIVITY; VERTIGO;

EID: 84879448876     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s36453     Document Type: Review

References (124)

1. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655-679.
2. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15(4):357-376.
3. Lenze E. Anxiety disorders in the elderly. In: Stein D, Hollander E, Rothbaum B, editors. Textbook of Anxiety Disorders, 2nd ed. Washington: American Psychiatric Publishing Inc; 2010:651-664.
4. Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiat Clin N Am. 2009a;32(3):483-524.
5. Angst J, Gamma A, Baldwin DS, Ajdacic-Gross V, Roessler W. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psy Clin N. 2009;259(1):37-45.
6. Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiat. 2005;162(6):1179-1187.
7. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiat. 2002;63:24-34.
8. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiat. 1999;156(12): 1915-1923.
9. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharm. 2000;15(6):319-328.
10. Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: Predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004;34(8): 1385-1394.
11. Beesdo K, Hoyer J, Jacobi F, Low NCP, Hofler M, Wittchen HU. Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. J Anxiety Disord. 23(5):684-693.
12. Allgulander C. Morbid anxiety as a risk factor in patients with somatic diseases: a review of recent findings. Mind Brain. 2010;1:1-9.
13. Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart Disease The Heart and Soul Study. Arch Gen Psychiat. 2010;67(7):750-758.
14. Safren S, Gershuny B, Marzol P, Otto M, Pollack M. History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis. 2002;190(7):453-456.
15. Rosenbaum J, Biederman J, Bolduc-Murphy E, et al. Behavioral inhibition in childhood: a risk factor for anxiety disorders. Harvard Rev Psychiat. 1993;1(1):2-16.
16. Kendler KS. Major depression and generalised anxiety disorder-Same genes, (partly) different environments-Revisited. Brit J Psychiat. 1996;168:68-75.
17. Hettema JM, Prescott CA, Kendler KS. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am J Psychiat. 2004;161(9):1581-1587.
18. Mackintosh MA, Gatz M, Wetherell JL, Pedersen NL. A twin study of lifetime generalized anxiety disorder (GAD) in older adults: genetic and environmental influences shared by neuroticism and GAD. Twin Res Hum Genet. 2006;9(1):30-37.
19. You JS, Hu SY, Chen BL, Zhang HG. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Gen. 2005;15(1):7-11.
20. Donner J, Sipila T, Ripatti S, et al. Support for involvement of glutamate decarboxylase 1 and neuropeptide y in anxiety susceptibility. Am J Med Genet B. 2012;159B(3):316-327.
21. Unschuld P, Ising M, Specht M, et al. Polymorphisms in the GAD-2 gene-region are associated with susceptibility for unipolar depression and with a risk factor for anxiety disorders. Am J Med Genet B. 2012;150B(8):1100-1109.
22. Verburg K, Griez E, Meijer J, Pols H. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am J Psychiat. 1995;152(7):1081-1083.
23. Cowley DS, Dager SR, McClellan J, Roybyrne PP, Dunner DL. Response to lactate infusion in generalized anxiety disorder. Biol Psychiatry. 1988;24(4):409-414.
24. Seddon K. Effects of 7.5% CO2 challenge in generalized anxiety disorder. J Psychopharmacol. 2011;25(1):43-51.
25. Bailey JE, Kendrick A, Diaper A, Potokar JP, Nutt DJ. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol. 2007;21:42-49.
26. Diaper A, Osman-Hicks V, Rich A, et al. Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. J Psychopharmacol. 2013;27: 135-145.
27. Beck A, Emery G, Greenberg R. Anxiety Disorders and Phobias: a Cognitive Perspective. New York: Basic Books; 1985.
28. Barlow D. Anxiety and Its Disorders: the Nature and Treatment of Anxiety and Panic. New York: Guilford; 1988.
29. Borkovec T, Alcaine O, Behar E. Avoidance theory of worry and generalized anxiety disorder. In: Heimberg R, Turk C, Mennin D, editors. Generalized Anxiety Disorder: advances in Research and Parctice. New York: Guilford; 2004:77-108.
30. Dugas MJ, Marchand A, Ladouceur R. Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord. 2005;19(3):329-343.
31. Wells A, King P. Metacognitive therapy for generalized anxiety disorder: An open trial. J Behav Ther Exp Psy. 2006;37(3):206-212.
32. Nitschke JB, Sarinopoulos I, Oathes DJ, et al. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiat. 2009;166(3):302-310.
33. Coles ME, Turk CL, Heimberg RG. Memory bias for threat in generalized anxiety disorder: the potential importance of stimulus relevance. Cognit Behav Ther. 2007;36(2):65-73.
34. MacLeod C, Mathews A, Tata P. Attentional bias in emotional disorders. J Abnorm Psychol. 1986;95(1):15-20.
35. Mathews A, Richards A, Eysenck M. Interpretation of homophones related to threat in anxiety states. J Abnorm Psychol. 1989;98:31.
36. Mogg K, Bradley BP, Millar N, White J. A follow-up study of cognitive bias in generalized anxiety disorder. Behav Res Ther. 1995;33(8): 927-935.
37. Mogg K, Baldwin DS, Brodrick P, Bradley BP. Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology (Berl). 2004;176(3-4):466-470.
38. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011a;14(5):697-710.
39. National Institute for Health and Clinical Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care. NICE Clinical Guideline 113. Manchester: National Institute for Health and Clinical Excellence; 2011.
40. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011b;342:d1199.
41. Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774-782.
42. Chessick CA, Allen HA, Thase ME, et al. Azapirones for generalized anxiety disorder [review]. Cochrane Database of Systematic Reviews. 2006;19:CD006115.
43. Lalonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics a systematic review and meta-analysis. J Clin Psychopharmacol. 2011;31(3):326-333.
44. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Syst Rev. 2010;8(12):CD006815.
45. Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiat. 1987;48(9): 355-358.
46. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharm. 2012;27(4):197-207.
47. Baldwin DS, Ajel K. The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3(2):185-191.
48. Micó J, Prieto R. Elucidating the mechanism of action of pregabalin: 4(2)(as a therapeutic target in anxiety. CNS Drugs. 2012;26(8):637-648.
49. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50(8):941-950.
50. Davies A, Kadurin I, Alvarez-Laviada A, et al. The alpha(2)delta subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function. Proc Natl Acad Sci U S A. 2010;107(4):1654-1659.
51. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci. 2007;28(5):220-228.
52. Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011;667(1-3):80-90.
53. Bian F, Li Z, Offord J, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006;1075:68-80.
54. Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha(2)-delta (alpha(2)-delta) type 1 protein. Neuroscience. 2008;155(2): 510-521.
55. Aupperle RL, Ravindran L, Tankersley D, et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacol. 2011;36(7):1466-1477.
56. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3): 424-429.
57. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharm. 2011;26(4):213-220.
58. Belliotti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J Med Chem. 2005;48(7):2294-2307.
59. Lotarski SM, Donevan S, El-Kattan A, et al. Anxiolytic-like activity of pregabalin in the vogel conflict test in alpha(2)delta-1 (R217A) and alpha(2)delta-2 (R279A) mouse mutants. J Pharmacol Exp Ther. 2011;338(2):615-621.
60. Eroglu C, Allen NJ, Susman MW, et al. Gabapentin receptor alpha 2 delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139(2):380-392.
61. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha(2)-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006;103(46):17537-17542.
62. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiat. 2003;160(3): 533-540.
63. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240-249.
64. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder-A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiat. 2005;62(9):1022-1030.
65. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder-Double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25(2):151-158.
66. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiat. 2006;67(5): 771-782.
67. Pande A, Crockatt M, Janney C, Feltner D. Pregabalin treatment of GAD. American Psychiatric Association 153rd Annual Meeting; May 13-18, 2006; Chicago, IL, USA.
68. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Brit J Psychiat. 2008;193(5):389-394.
69. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharm. 2009;24(2):87-96.
70. Feltner D, Wittchen H-U, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharm. 2008;23(1):18-28.
71. Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharm. 2012;27(3):142-150.
72. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864-872.
73. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders-A meta-analysis. J Affect Disord. 2010;123(1-3):9-16.
74. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiat. 2005;66(10):1321-1325.
75. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211-215.
76. Altamura AC, Serati M, Buoli M, Dell'Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharm. 2011;26(4):201-205.
77. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008; 197(4):675-681.
78. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010; 30(2):185-189.
79. Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo-and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol. 2009;23(8):867-873.
80. Gonano C, Latzke D, Sabeti-Aschraf M, Kettner SC, Chiari A, Gustorff B. The anxiolytic effect of pregabalin in outpatients undergoing minor orthopaedic surgery. J Psychopharmacol. 2011;25(2): 249-253.
81. Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008;42(14):1176-1184.
82. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269-275.
83. Baldwin DS, Schweizer E, Xu Y, Lyndon G. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? Eur Neuropsychopharmacol. 2012;22(2):137-142.
84. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007;40(4):163-168.
85. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
86. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010;13(2):229-241.
87. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18(6):422-430.
88. Montgomery SA, Herman BK, Schweizer E, Mandel FS. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharm. 2009;24(4):214-222.
89. Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol. 2012;25: 1-12.
90. Pegg D, Bleavins M, Herman J, et al. Hemangiosarcoma in mice administered pregabalin: analysis of genotoxicity, tumor incidence, and tumor genetics. Toxicol Sci. 2012;128(1):9-21.
91. Criswell KA, Wojcinski Z, Pegg D, et al. Key components of the mode of action for hemangiosarcoma induction in pregabalin-treated mice: evidence of increased bicarbonate, dysregulated erythropoiesis, macrophage activation, and increased angiogenic growth factors in mice but not in rats. Toxicol Sci. 2012;128(1):22-41.
92. Criswell KA, Cook JC, Morse D, et al. Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation. Toxicol Sci. 2012; 128(1):42-56.
93. Criswell KA, Cook JC, Wojcinski Z, et al. Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance. Toxicol Sci. 2012;128(1): 57-71.
94. European Medicines Agency. Lyrica (pregabalin). 2013. Available from:www.emea.europa.eu/humandocs/Humans/EPAR/lyrica/lyrica.htm. Accessed March 20, 2013.
95. Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across different disorders: a meta-analysis. European Journal of Clinical Pharmacology. 2012;68(6):903-912.
96. Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Safety. 2012;35(10):793-806.
97. Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639-656.
98. Wustmann T, Piro J, Gutmann P. Metabolic considerations in a case of pregabalin-induced edema. Pharmacopsychiatry. 2009;42(2):75-76.
99. Krueger S, Lindstaedt M. Pregabalin and edema in young women suffering from premenstrual syndrome. Pharmacopsychiatry. 2010;43(5):202-203.
100. Guzelkucuk U, Duman I, Yilmaz B, Tan AK. Reversible post-pregabalin peripheral edema in a spinal cord injury patient. Spinal Cord. 2012;50(6):472-473.
101. Gallagher R, Apostle N. Peripheral edema with pregabalin. CMAJ. [Epub November 5, 2012.]
102. Sendra JM, Junyent TT, Pellicer MJR. Pregabalin-induced hepatotoxicity. Ann Pharmacother. 2011;45(6):e32-e32.
103. Erdogan G, Ceyhan D, Gulec S. Possible heart failure associated with pregabalin use: case report. Agri. 2011;23(2):80-83.
104. Aksakal E, Bakirci EM, Emet M, Uzkeser M. Complete atrioventricular block due to overdose of pregabalin. Am J Emerg Med. 2012;30(9).
105. Sjoberg G, Feychting K. Pregabalin Overdose in Adults and Adolescents-Experience in Sweden. Clin Toxicol. 2010;48(3):282-282.
106. Wood DM, Berry DJ, Glover G, Eastwood J, Dargan PI. Significant pregabalin toxicity managed with supportive care alone. J Med Toxicol. 2010;6(4):435-437.
107. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol. 2006;16:S128-S133.
108. Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav. 2012;100(3):560-565.
109. Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiat. 2010;167(7):869-869.
110. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110(10):605-607.
111. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947-953.
112. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2):118-122.
113. Gahr M, Freudenmann R, Hiemke C, Kölle M, Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335-1342.
114. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol. 2008;23(4):337-340.
115. Oulis P, Masdrakis VG, Karakatsanis NA, et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharm. 2008;23(2):110-112.
116. Oulis P, Nakkas G, Masdrakis VG. Pregabalin in zolpidem dependence and withdrawal. Clin Neuropharmacol. 2011;34(2):90-91.
117. Bobes J, Rubio G, Teran A, et al. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry. 2012;27(4):301-307.
118. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461-470.
119. Stopponi S, Somaini L, Cippitelli A, et al. Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology (Berl). 2012;220(1):87-96.
120. Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41(4):399-406.
121. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012; 29(11):947-957.
122. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2008;9(4): 248-312.
123. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry. 2012;13(7):510-516.
124. Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84.